Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian equity markets remain in red
Wed, 12 Jun 11:30 am

Indian equity markets have remained in red during the previous two hours of trade. oil and gas and healthcare sectors are leading the gains while metals and consumer durables are facing the maximum selling pressures.

The BSE-Sensex is down by 95 points and NSE-Nifty is down by 26 points. BSE Mid Cap index is down by 0.3% while BSE Small Cap index is down by 0.1%. The rupee is trading at 56.32 to the US dollar.

IT shares are trading on a mixed note with Info Edge and Mahindra Satyam leading the gains while TCS and Moser-Baer India are leading the losses. According to a leading financial news daily, India's second largest software exporter, Infosys has hired executive search firm, Egon Zehnder to identify and shortlist possible external candidates on a global basis, who can be considered for the position of chief executive officer. While it does not necessarily imply that an outsider would be appointed as the next CEO, it does highlight the fact that there has been a change in mindset at Infosys. Infosys has been recently drawing a lot of criticism from the investor community on account of its share price underperformance. While a part of that is attributable to the change in strategy adopted by the company, i.e. to focus more on value-added services rather than plain-vanilla application development and maintenance, a part of the underperformance can also be attributed to rapid changes in top management that has happened in quick succession. On June 1, in an unusual move, the Bangalore based company recalled retired co-founder NR Narayana Murthy as the executive chairman for five years. Infosys' share is trading up by 0.7%.

Indian Pharma shares are trading on a mixed note with IPCA Labs and Glenmark Pharma leading the gains while Dishman Pharma and Wockhardt Ltd are facing the maximum selling pressures. According to a leading financial news daily, Government of India has banned the sale of analgesic drug Dextropropoxyphene that is used as a painkiller mostly in combination with Paracetamol or Dicyclomine in a number of drug brands including Wockhardt's Proxyvon and Ranbaxy's Sudhinol. The government is of the opinion that the use of the aforesaid drug and formulations containing the aforesaid drug is likely to involve risk to human beings. In India, this drug registers over Rs 700 m of sale and is marketed by over a dozen players. Drug brands likely to get affected by the ruling include Wockhardt's Proxyvon and Spasmo-Proxyvon, Ranbaxy Lab's Sudhino, Lupin's Lupivon and Wallace's Walagesic. The drug was taken off from the US market in 2010 for serious side effects related to heart and risk of fatal overdose. The UK and some other European markets banned it between 2007 and 2009.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Indian equity markets remain in red". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 23, 2018 (Close)


  • Track your investment in INFOSYS LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks